Prediction of preterm pre-eclampsia at midpregnancy using a multivariable screening algorithm

被引:7
作者
Black, Carin [1 ,2 ]
Rolnik, Daniel Lorber [3 ,4 ]
Al-Amin, Ahmed [5 ,6 ]
Kane, Stefan C. [1 ,2 ,5 ]
Stolarek, Caroline [1 ]
White, Adrienne [1 ]
Da Silva Costa, Fabricio [3 ,7 ]
Brennecke, Shaun [1 ,2 ]
机构
[1] Royal Womens Hosp, Dept Maternal Fetal Med, Pregnancy Res Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Royal Womens Hosp, Dept Obstet & Gynaecol, Melbourne, Vic, Australia
[3] Monash Univ, Dept Obstet & Gynaecol, Melbourne, Vic, Australia
[4] Monash Med Ctr, Perinatal Serv, Melbourne, Vic, Australia
[5] Royal Womens Hosp, Pauline Gandel Imaging Ctr, Melbourne, Vic, Australia
[6] Monash Ultrasound Women, Melbourne, Vic, Australia
[7] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynecol & Obstet, Ribeirao Preto, SP, Brazil
关键词
multivariable algorithm; placental growth factor (PlGF); prediction; pre-eclampsia; second trimester; HYPERTENSIVE DISORDERS; BIOCHEMICAL MARKERS; MATERNAL FACTORS; PREGNANCY; CLASSIFICATION; BIOMARKERS; MANAGEMENT; DIAGNOSIS; ASPIRIN; DOPPLER;
D O I
10.1111/ajo.13113
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background Competing risk models used for midpregnancy prediction of preterm pre-eclampsia have shown detection rates (DR) of 85%, at fixed false-positive rate (FPR) of 10%. The full algorithm used between 19(+0) and 24(+6) weeks includes maternal factors, mean arterial pressure (MAP), mean uterine artery pulsatility index (UtAPI), serum placental growth factor (PlGF) level in multiples of the median (MoM), and soluble Fms-like tyrosine kinase-1 (sFlt-1) level in MoM. Aims To assess performance of the Fetal Medicine Foundation (FMF) algorithm at midpregnancy to screen for preterm (<37 weeks) pre-eclampsia. The outcome measured was preterm pre-eclampsia. Materials and Methods This is a prospective study including singleton pregnancies at 19-22 weeks gestation. Maternal bloods were collected and analysed using three different immunoassay platforms. Maternal characteristics, medical history, MAP, mean UtAPI, serum PlGF MoM and serum sFlt-1 MoM were used for risk assessment. DR and FPR were calculated, and receiver operating characteristic curves produced. Results Five hundred and twelve patients were included. Incidence of preterm pre-eclampsia was 1.6%. Using predicted risk of pre-eclampsia of one in 60 or more and one in 100 or higher, as given by the FMF predictive algorithm, the combination with the best predictive performance for preterm pre-eclampsia included maternal factors, MAP, UtAPI and PlGF MoM, giving DRs of 100% and 100%, respectively, and FPRs of 9.3 for all platforms and 12.9-13.5, respectively. Addition of sFlt-1 to the algorithm did not appear to improve performance. sFlt-1 MoM and PlGF MoM values obtained on the different platforms performed very similarly. Conclusions Second trimester combined screening for preterm pre-eclampsia by maternal history, MAP, mean UtAPI and PlGF MoM using the FMF algorithm performed very well in this patient population.
引用
收藏
页码:675 / 682
页数:8
相关论文
共 30 条
[21]   Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy [J].
Park, Felicity J. ;
Leung, Constance H. Y. ;
Poon, Leona C. Y. ;
Williams, Paul F. ;
Rothwell, Samantha J. ;
Hyett, Jon A. .
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2013, 53 (06) :532-539
[22]   Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia [J].
Plasencia, W. ;
Maiz, N. ;
Bonino, S. ;
Kaihura, C. ;
Nicolaides, K. H. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2007, 30 (05) :742-749
[23]   Protocol for Measurement of Mean Arterial Pressure at 11-13 Weeks' Gestation [J].
Poon, L. C. Y. ;
Zymeri, N. A. ;
Zamprakou, A. ;
Syngelaki, A. ;
Nicolaides, K. H. .
FETAL DIAGNOSIS AND THERAPY, 2012, 31 (01) :42-48
[24]   Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks [J].
Poon, L. C. Y. ;
Akolekar, R. ;
Lachmann, R. ;
Beta, J. ;
Nicolaides, K. H. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2010, 35 (06) :662-670
[25]   Early Administration of Low-Dose Aspirin for the Prevention of Preterm and Term Preeclampsia: A Systematic Review and Meta-Analysis [J].
Roberge, Stephanie ;
Villa, Pia ;
Nicolaides, Kypros ;
Giguere, Yves ;
Vainio, Merja ;
Bakthi, Abdelouahab ;
Ebrashy, Alaa ;
Bujold, Emmanuel .
FETAL DIAGNOSIS AND THERAPY, 2012, 31 (03) :141-146
[26]  
Sentilhes L, 2017, NEW ENGL J MED, V377, P2399, DOI [10.1056/NEJMc1713798, 10.1056/NEJMoa1704559]
[27]   The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP [J].
Tranquilli, A. L. ;
Dekker, G. ;
Magee, L. ;
Roberts, J. ;
Sibai, B. M. ;
Steyn, W. ;
Zeeman, G. G. ;
Brown, M. A. .
PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2014, 4 (02) :97-104
[28]   The incidence of preeclampsia and eclampsia in Australia: 2000 through 2008 [J].
Vlachadis, Nikolaos ;
Iliodromiti, Zoe ;
Vrachnis, Nikolaos .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2014, 210 (02) :173-174
[29]   Predictive performance of the competing risk model in screening for preeclampsia [J].
Wright, David ;
Tan, Min Yi ;
O'Gorman, Neil ;
Poon, Liona C. ;
Syngelaki, Argyro ;
Wright, Alan ;
Nicolaides, Kypros H. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 220 (02) :199.e1-199.e13
[30]   A Competing Risks Model in Early Screening for Preeclampsia [J].
Wright, David ;
Akolekar, Ranjit ;
Syngelaki, Argyro ;
Poon, Leona C. Y. ;
Nicolaides, Kypros H. .
FETAL DIAGNOSIS AND THERAPY, 2012, 32 (03) :171-178